This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Novartis Pharma AG.
Reference
Viriato D, et al. An Economic Evaluation of Voretigene Neparvovec for the Treatment of Biallelic RPE65-Mediated Inherited Retinal Dystrophies in the UK. Advances in Therapy : 7 Feb 2020. Available from: URL: http://doi.org/10.1007/s12325-020-01243-y
Rights and permissions
About this article
Cite this article
Voretigene neparvovec good value in inherited retinal dystrophies. PharmacoEcon Outcomes News 847, 35 (2020). https://doi.org/10.1007/s40274-020-6611-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6611-1